Funder: National Institutes of Health

Due Dates: June 4, 2025 (New/Renewal/Resubmission/Revision) | September 7, 2025 (AIDS) | October 2, 2025 (New/Renewal/Resubmission/Revision) | January 7, 2026 (AIDS) | February 3, 2026 (New/Renewal/Resubmission/Revision) | May 7, 2026 (AIDS) | June 4, 2026 (New/Renewal/Resubmission/Revision) | September 7, 2026 (AIDS) | October 2, 2026 (New/Renewal/Resubmission/Revision) | January 7, 2027 (AIDS)

Funding Amounts: Up to $1,515,000 in direct costs per year, for a maximum of 3 years (R33 mechanism).

Summary: Supports investigator-initiated, early phase (Phase I) clinical trials for diagnostic or therapeutic interventions in heart, lung, blood, and sleep (HLBS) disorders in adults and children.

Key Information: Applicants must be ready to initiate the clinical trial within the first quarter of the project period; regulatory approvals and trial readiness must be in place by the time of award.